Install the app
How to install the app on iOS

Follow along with the video below to see how to install our site as a web app on your home screen.

Note: This feature may not be available in some browsers.


ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

E

EGBOT

Guest
ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

HTML:
Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.

Source: ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients
 

Create an account or login to comment

You must be a member in order to leave a comment

Create account

Create an account on our community. It's easy!

Log in

Already have an account? Log in here.

Latest threads

Back
Top